and NK cells in a dose-dependent manner, and reduces growth of established tumors in vivo. This preclinical data, demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors.  

**Ethics Approval**  
Treatment of study animals was in accordance with conditions specified in the Guide for the Care and Use of Laboratory Animals, and the study protocol (ACUP 20) was approved by the Institutional Animal Care and Use Committee (IACUC).  

**REFERENCES**  

**Immunotherapy toxicities**

**637** IMMUNE-RELATED ADVERSE EVENTS (IRAES) MAY INDICATE A FAVORABLE PROGNOSIS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)  

1*Dylan Martin*, 2Sean Evans, 3Subir Goyal, 1Yuan Liu, 1Anders Olsen, 1Benjamin Magid, 1Jacqueline Brown, 1Lauren Yantorno, 1Greta Russler, 1Sarah Caulfield, 1Jimmie Goldman, 1Bassel Nazha, 1Wayne Harris, 1ViraJ Master, 1Omer Kucuk, 1Bradley Carthon, 1Jacqueline Brown, 1Lauren Yantorno, 1Greta Russler, 1Sarah Caulfield, 1Jimmie Goldman, 1Bassel Nazha, 1Wayne Harris, 1ViraJ Master, 1Omer Kucuk, 1Bradley Carthon, 1Emory University School of Medicine, Atlanta, GA, USA; 2Winship Cancer Institute of Emory University, Atlanta, GA, USA

**Background** Immune checkpoint inhibitors (ICI) have become an increasingly utilized treatment in metastatic renal